NO20053947L - Forbedrede antitumorale behandlinger. - Google Patents

Forbedrede antitumorale behandlinger.

Info

Publication number
NO20053947L
NO20053947L NO20053947A NO20053947A NO20053947L NO 20053947 L NO20053947 L NO 20053947L NO 20053947 A NO20053947 A NO 20053947A NO 20053947 A NO20053947 A NO 20053947A NO 20053947 L NO20053947 L NO 20053947L
Authority
NO
Norway
Prior art keywords
improved antitumoral
antitumoral treatments
treatments
improved
treatment
Prior art date
Application number
NO20053947A
Other languages
English (en)
Other versions
NO20053947D0 (no
Inventor
Jose Jimeno
Debabrata Barnejee
Joseph R Bertino
Saydam Guray
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20053947D0 publication Critical patent/NO20053947D0/no
Publication of NO20053947L publication Critical patent/NO20053947L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sammendrag Aplidin og aplidinanaloger kan benyttes for behandling av cancer, særlig for behandling av leukemier og lymfomer, og særlig ved kombinasjonsterapi.
NO20053947A 2003-03-12 2005-08-24 Forbedrede antitumorale behandlinger. NO20053947L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
PCT/US2004/007606 WO2004080421A2 (en) 2003-03-12 2004-03-12 Improved antitumoral treatments

Publications (2)

Publication Number Publication Date
NO20053947D0 NO20053947D0 (no) 2005-08-24
NO20053947L true NO20053947L (no) 2005-12-07

Family

ID=32990868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053947A NO20053947L (no) 2003-03-12 2005-08-24 Forbedrede antitumorale behandlinger.

Country Status (13)

Country Link
US (2) US7576188B2 (no)
EP (1) EP1620117A4 (no)
JP (1) JP2006519848A (no)
KR (1) KR20060002778A (no)
CN (3) CN100409895C (no)
AU (1) AU2004220451B2 (no)
CA (1) CA2516572A1 (no)
MX (1) MXPA05009741A (no)
NO (1) NO20053947L (no)
NZ (1) NZ541634A (no)
RU (1) RU2341283C2 (no)
UA (2) UA83022C2 (no)
WO (1) WO2004080421A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CN1423564A (zh) * 1999-11-15 2003-06-11 法马马有限公司 癌症的aplidine治疗
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CZ2003993A3 (cs) 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
ATE406171T1 (de) 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
CN101389347B (zh) * 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
WO2008135793A1 (en) * 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
US20110009335A1 (en) * 2008-03-07 2011-01-13 Pharma Mar, S.A. Anticancer Treatments
WO2010029158A1 (en) * 2008-09-12 2010-03-18 Pharma Mar, S.A. Aplidine in the treatment of chronic myeloproliferative disorders
CN104706599B (zh) * 2013-12-11 2020-10-02 中国海洋大学 一种携带膜海鞘素化合物的冻干粉针剂
CN109462980B (zh) * 2016-03-15 2022-02-08 奥莱松基因组股份有限公司 用于治疗血液恶性肿瘤的lsd1抑制剂的组合
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) * 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5018188A (en) 1989-12-20 1991-05-21 Motorola, Inc. Microphone-controller with multifunction, single conductor
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5482726A (en) * 1992-07-14 1996-01-09 Us Harvest Technologies Corporation Method for reducing contamination of shellfish
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
CA2259441A1 (en) 1996-07-03 1998-01-15 Andrew Christopher Cope Containers
PT956033E (pt) 1996-10-24 2003-10-31 Univ Illinois SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A
DE69735583T2 (de) 1996-10-24 2007-04-05 The Board Of Trustees Of The University Of Illinois, Urbana Semisynthetisches verfahren zur herstellung von didemninanalogen
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
EP0981352B8 (en) * 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9821975D0 (en) * 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
CN1423564A (zh) * 1999-11-15 2003-06-11 法马马有限公司 癌症的aplidine治疗
SE9904175D0 (sv) 1999-11-18 1999-11-18 Pharmacia & Upjohn Diag Ab Assay device and use thereof
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
CA2411102A1 (en) * 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU9402401A (en) 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
CZ2003993A3 (cs) * 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
JP2004521112A (ja) * 2001-01-24 2004-07-15 メステックス アクチエンゲゼルシャフト 関節痛治療薬を製造することへの神経毒性物質の使用
ATA13422001A (de) 2001-08-23 2003-09-15 Plasser Bahnbaumasch Franz Maschine zur bearbeitung einer gleisbettung
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
ATE406171T1 (de) 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
WO2004080421A2 (en) * 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
RU2005126819A (ru) 2006-01-20
CN1761480A (zh) 2006-04-19
MXPA05009741A (es) 2005-11-16
AU2004220451A1 (en) 2004-09-23
EP1620117A4 (en) 2009-07-29
AU2004220451B2 (en) 2010-01-21
UA83022C2 (uk) 2008-06-10
CN101579520A (zh) 2009-11-18
US20060178298A1 (en) 2006-08-10
CN1753684A (zh) 2006-03-29
NO20053947D0 (no) 2005-08-24
NZ541634A (en) 2008-08-29
UA82089C2 (uk) 2008-03-11
RU2341283C2 (ru) 2008-12-20
WO2004080421A3 (en) 2005-06-09
US7576188B2 (en) 2009-08-18
CN100409895C (zh) 2008-08-13
JP2006519848A (ja) 2006-08-31
WO2004080421A2 (en) 2004-09-23
CN1761480B (zh) 2012-09-26
US20090227490A1 (en) 2009-09-10
CA2516572A1 (en) 2004-09-23
KR20060002778A (ko) 2006-01-09
EP1620117A2 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
NO20053947L (no) Forbedrede antitumorale behandlinger.
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2006015263A3 (en) Lonidamine analogs
NO20071714L (no) Fremgangsmateer for behandling av CD30 positive lymfomer
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
TW200505434A (en) Therapeutic treatment
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
WO2004012662A3 (en) Improved treatment of cancer with glutamine
WO2002076548A3 (en) Methods and apparatus for treating diseased tissue
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
AU9678501A (en) Pharmaceutical solutions of modafinil compounds
WO2007047608A3 (en) Fibrin targeted therapeutics
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
ATE442188T1 (de) Bestrahlungseinrichtung
IL159770A0 (en) Calcium salts with cytotoxic activity
ECSP013869A (es) Tratamiento del dolor
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
AU2003229876A1 (en) Tumour associated antigens
WO2006004774A3 (en) Laulimalide analogues as therapeutic agents
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
EP1417968A3 (en) Antitumour compositions containing propolis and resveratrol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application